

Lund, Figliola,
Kajetanowicz and Thompson

Prodigiosenes Bearing C-Ring Esters and Amides

Synthesis and Anticancer Activity of Prodigiosenes bearing C-Ring Esters and Amides

Kate-lyn A. R. Lund, Carlotta Figliola, Aleksandra K. Kajetanowicz and Alison Thompson*

Department of Chemistry, Dalhousie University, P.O. Box 15000, Halifax, Nova Scotia, Canada, B3H 4R2

Supporting Information

Table of Contents

NCI DATA REPORTED USING DRUG CONCENTRATION VALUES	2
NMR SPECTRA	4
Benzyl 3-(3-ethoxy-3-oxopropyl)-4-(3-methoxy-3-oxopropyl)-5-methyl-1H-pyrrole-2-carboxylate (1)	4
4-[(Methoxycarbonyl)ethyl]-3-[2-(ethoxycarbonyl)ethyl]-5-methyl pyrrole-2-carboxaldehyde (3)	5
4-(Benzylmethanoate)-3[(methoxycarbonyl)ethyl]-5-methyl pyrrole-2-carboxaldehyde (4)	6
(Z)-Ethyl 3-(4-(3-methoxy-3-oxopropyl)-2-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-5-methyl-1H-pyrrol-3-yl)propanoate (5)	7
(Z)-Benzyl 4-(3-(3-methoxy-3-oxopropyl)-2-(3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-5-methyl-1H-pyrrol-3-yl)formate (6)	8
(Z)-Ethyl 3-(2-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-4-(3-methoxy-oxopropyl)-5-methyl-1H-pyrrol-3-yl)propanoate (7)	9
(Z)-Benzyl 4-(2-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-3-(3-methoxy-3-oxopropyl)-5-methyl-1H-pyrrol-3-yl)formate (8)	10
(Z)-Ethyl 3-(2-((4-methoxy-1H-1H'-[2,2'-bipyrrol]-5-yl)methylene)-4-(3-methoxy-3-oxopropyl)-5-methyl-2H-pyrrol-3-yl)propanoate hydrochloride (9•HCl)	11
(Z)-Benzyl 4-(2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3-(3-methoxy-3-oxopropyl)-5-methyl-2H-pyrrol-3-yl)formate (10•HCl)	12
(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4-(2-methoxy-2-oxoethyl)-5-methyl-2H-pyrrol-3-yl)propanoate (13•HCl)	13
(Z)-Methyl 3-(2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4,5-dimethyl-2H-pyrrol-3-yl)propanoate) (14•HCl)	14
(Z)-Benzyl 2-(2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetate (15a•HCl)	15
(Z)-Hexyl 2-(2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetate (15b•HCl)	16
(Z)-Neopentyl 2-(2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetate hydrochloride (15c•HCl)	17
(Z)-Benzyl 2-(2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetamide hydrochloride (15d•HCl)	18
(Z)-Butyl 2-(2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetamide hydrochloride (15e•HCl)	19
(Z)-N,N-Diethyl 2-(2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetamide hydrochloride (15f•HCl)	20

NCI data reported using drug concentration values

Compound	Mean GI ₅₀ ^a (μM)	Mean TGI ^b (μM)	Mean LC ₅₀ ^c (μM)	tPSA (Å ²)
Prodigiosin	0.014	2.1	0.22	45.65
Prodigiosin-Me	0.015	0.14	1.1	45.65
10	0.85	4.9	45	98.25
11	3.5	15	51	98.25
12	0.54	5.4	30	71.95
13	0.37	2.5	28	98.25
14	0.35	2.0	17	71.95
15	0.2	2.3	20	71.95
15a	0.32	1.8	16	71.95
15b	0.091	1.0	5.9	71.95
15c	0.22	1.2	5.5	71.95
15d	1.4	3.0	6.0	74.75
15e	2.4	8.7	46	74.75
15f	0.48	11	65	65.96

Table 1S. Mean *in vitro* activity of prodigiosin (**1**) and prodigiosenes **2b-d**, **3-11** over 60 cancer cell lines; (<http://dtp.cancer.gov>); ^aGI₅₀ = half maximal growth inhibition concentration; ^bTGI = total growth inhibition concentration; ^cLC₅₀ = half maximal lethal concentration.




Figure 1S: GI_{50} concentrations (half maximal growth inhibition concentrations) of prodigiosenes 15, 15a, 15b, 15e and 15f against the NCI-60 human cancer cell lines representing 9 different cancer types; see <http://http.dtp.cancer.gov>






Figure 2S: GI_{50} concentrations (half maximal growth inhibition concentrations) of prodigiosenes 10, 11, 13 and 14 against the NCI-60 human cancer cell lines representing 9 different cancer types; see <http://http.dtp.cancer.gov>

NMR Spectra


*Benzyl 3-(3-ethoxy-3-oxopropyl)-4-(3-methoxy-3-oxopropyl)-5-methyl-1*H*-pyrrole-2-carboxylate (I)*




^1H NMR; 300 MHz, CDCl_3




^{13}C NMR; 125 MHz, CDCl_3




4-[(Methoxycarbonyl)ethyl]-3-[2-(ethoxycarbonyl)ethyl]-5-methyl pyrrole-2-carboxaldehyde (3)




^1H NMR; 300 MHz, CDCl_3




^{13}C NMR; 75 MHz, CDCl_3




4-(Benzylmethanoate)-3[(methoxycarbonyl)ethyl]-5-methyl pyrrole-2-carboxaldehyde (4)




¹H NMR; 300 MHz, CDCl₃




¹³C NMR; 125 MHz, CDCl₃




(Z)-Ethyl 3-(4-(3-methoxy-3-oxopropyl)-2-((3-methoxy-5-oxo-1H-pyrrol-2(5H)-ylidene)methyl)-5-methyl-1H-pyrrol-3-yl)propanoate (5)




¹H NMR; 500 MHz, CDCl₃




¹³C NMR; 125 MHz, CDCl₃




(Z)-Benzyl 4-(3-(3-methoxy-3-oxopropyl)-2-(3-methoxy-5-oxo-1H-pyrrole-2(5H)-ylidene)methyl)-5-methyl-1H-pyrrrol-3-yl)formate (6)




¹³C NMR; 125 MHz, DMSO




(Z)-Ethyl 3-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-4-(3-methoxy-oxopropyl)-5-methyl-1H-pyrrol-3-yl)propanoate (7)



¹H NMR; 500 MHz, CDCl₃




¹³C NMR; 125 MHz, CDCl₃




(Z)-Benzyl 4-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-3-(3-methoxy-3-oxopropyl)-5-methyl-1H-pyrrol-3-yl)formate (8)


MeO₂C




¹H NMR; 500 MHz, CDCl₃




¹³C NMR; 125 MHz, CDCl₃




(Z)-Ethyl 3-((4-methoxy-1H-1H-[2,2'-bipyrrol]-5-yl)methylene)-4-(3-methoxy-3-oxopropyl)-5-methyl-2H-pyrrol-3-yl)propanoate hydrochloride (9•HCl)




¹H NMR; 500 MHz, CDCl₃




¹³C NMR; 500 MHz, CDCl₃




(Z)-Benzyl 4-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3-(3-methoxy-3-oxopropyl)-5-methyl-2H-pyrrol-3-yl)formate (10•HCl)




¹H NMR; 500 MHz, CDCl₃




¹³C NMR; 125 MHz, CDCl₃




(Z)-Methyl 3-((2-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4-(2-methoxy-2-oxoethyl)-5-methyl-2H-pyrrol-3-yl)propanoate (13•HCl)




¹H NMR; 500 MHz, CDCl₃




¹³C NMR; 125 MHz, CDCl₃




(Z)-Methyl 3-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)-4,5-dimethyl-2H-pyrrol-3-yl)propanoate (14•HCl)




¹H NMR; 500 MHz, CDCl₃




¹³C NMR; 125 MHz, CDCl₃




(Z)-Benzyl 2-(2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetate (15a•HCl)





¹H NMR; 300 MHz, CDCl₃




¹³C NMR; 125 MHz, CDCl₃







¹H NMR; 500 MHz, CDCl₃




¹³C NMR; 125 MHz, CDCl₃




(Z)-Neopentyl 2-(2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetate hydrochloride (15c•HCl)




(Z)-Benzyl 2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetamide hydrochloride (15d•HCl)




¹H NMR; 300 MHz, CDCl₃




¹³C NMR; 125 MHz, CDCl₃




(Z)-Butyl 2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetamide hydrochloride (15e•HCl)




¹H NMR; 300 MHz, CDCl₃




¹³C NMR; 125 MHz, CDCl₃



(Z)-N,N-Diethyl 2-(2-((4-methoxy-1H,1H'-[2,2'-bipyrrol]-5-yl)methylene)-3,5-dimethyl-2H-pyrrol-4-yl)acetamide hydrochloride (15f•HCl)



¹H NMR; 300 MHz, CDCl₃



¹³C NMR; 125 MHz, CDCl₃

